雅本化學(300261.SZ):一季度淨利潤預增8.96%-23.35%
格隆匯4月7日丨雅本化學(300261.SZ)披露2020年第一季度業績預告,預計歸屬於上市公司股東的淨利潤5300萬元–6000萬元,同比增長8.96%-23.35%。業績變動原因如下:
報告期內,公司生產經營穩定,農藥、醫藥產品訂單情況良好;作為公司主要旗艦製造基地的南通雅本,新冠疫情期間在確保員工生命健康、疫情防控到位的前提下,有序組織安全生產,保障了國際農藥定製業務的正常開展,同時通過技術提升降低了生產成本,有效提高產品收率和盈利能力;其他生產基地(除濱海基地外)已於2020年3月陸續復工,公司正積極推進濱海基地復產事宜,新冠疫情未對公司生產經營造成重大影響;醫藥業務平穩發展,公司不斷優化調整產品結構,生物酶協同作用逐漸增強,部分產品毛利率有所提升。
公司2020年第一季度非經常性損益大約為-400萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.